5 out 2016 ano - FDA convened a joint meeting of the Anesthetic
and Analgesic Drug Products Advisory Committee
and the Drug Safety and Risk Management to
discuss naloxone products intended for use in
the community, specifically the most appropriate
dose or doses of naloxone to reverse the effects
of life-threatening opioid overdose in all ages.
Adicionado na linha do tempo:
Opioids and the FDA
Data:
